United States

People: Illumina Inc (ILMN.O)

ILMN.O on Nasdaq

26 Jul 2017
Change (% chg)

$2.45 (+1.41%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Eastham, Karin 

Ms. Karin Eastham, CPA, is Independent Director of Illumina, Inc. since July 2004. Ms. Eastham serves on the boards of directors for several life science companies. From May 2004 to September 2008, she served as Executive Vice President and Chief Operating Officer, and as a member of the Board of Trustees, of Burnham Institute for Medical Research, a non-profit corporation engaged in basic biomedical research. From 1999 to 2004, Ms. Eastham served as Senior Vice President, Finance, Chief Financial Officer and Secretary of Diversa Corporation, a biotechnology company. She previously held similar positions with CombiChem, Inc. a computational chemistry company, and Cytel Corporation, a biopharmaceutical company. Ms. Eastham also held several positions, including Vice President, Finance, at Boehringer Mannheim Corporation, a biopharmaceutical company, from 1976 to 1988. Ms. Eastham also serves as a director for MorphoSys AG, a Frankfurt Stock Exchange-listed biotechnology company; Geron Corporation, a NASDAQ-listed biopharmaceutical company; Trius Therapeutics, Inc. a NASDAQ-listed biopharmaceutical company; and Veracyte, Inc. a privately-held molecular diagnostics company. Ms. Eastham also served as a past director of Amylin Pharmaceuticals, Inc. a NASDAQ-listed biopharmaceutical company, from 2005 until its sale to Bristol-Myers-Squibb Company in 2012; Genoptix, Inc. a NASDAQ-listed provider of specialized diagnostic laboratory services, from 2008 until its sale to Novartis AG in 2011; Tercica, Inc. a NASDAQ-listed biopharmaceutical company, from 2003 until its sale to Beaufour Ipsen Pharma in 2008; and SGX Pharmaceuticals, Inc., a NASDAQ-listed biopharmaceutical company, from 2005 until its sale to Eli Lilly and Company in 2008. Ms. Eastham received a B.S. and an M.B.A. from Indiana University and is a Certified Public Accountant.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Awards, USD 400,076
Long-Term Incentive Plans, USD --
All Other, USD 90,000
Fiscal Year Total, USD 490,076

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Jay Flatley


Francis deSouza


Sam Samad


Marc Stapley


Garret Hampton


Omead Ostadan

As Of  31 Dec 2016